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There is a pressing need for new anticonvulsants for children and 
adults with medically refractory epilepsy. Neuropeptides such as 
neuropeptide Y (NPY) and galanin are promising because they 
have anticonvulsant effects in seizure models (1–5). However, the 
potential of neuropeptides as anticonvulsants remains unexploit-
ed except for adrenocorticotropic hormone, an accepted treatment 
for some childhood epilepsies (6). One factor limiting the clini-
cal utility of neuropeptides such as NPY and galanin is that they 
are not suited for peripheral administration because they do not 
cross the blood-brain barrier. Thus, the peptide leptin may have 
a clinical advantage because it has anticonvulsant properties and 
crosses the blood-brain barrier via a transport system (7). Leptin 
is potentially easy to administer because i.n. leptin administration 
produces rapid, substantial increases in serum, cerebrospinal fluid, 
and brain leptin levels (8, 9).
Leptin receptor expression has been reported in the hippo-
campus and neocortex (10–12), but its functional role is poorly 
understood. Recent studies in primary neuronal cultures and 
hippocampal slices have characterized some of leptin’s anticon-
vulsant properties beyond its role in regulating energy homeosta-
sis. In these studies leptin suppressed epileptiform-like bursting 
and elevations in intracellular calcium under low extracellular 
magnesium conditions by opening large-conductance calcium-
activated neuronal potassium (BK) channels (11, 13, 14). Leptin 
also induces long-term depression (LTD) under these conditions 
(15). These results, combined with our and others’ observations 
that ketogenic diets elevate serum leptin levels in rodents (16, 17), 
motivated us to try to link leptin to the anticonvulsant effects 
of ketogenic diets (i.e., high-fat, low-carbohydrate, and adequate-
protein diets) sometimes used to treat intractable epilepsy (18). 
We hypothesized that leptin may contribute to some of the anti-
convulsant effects of ketogenic diets.
We recognize that leptin may be a proconvulsant. For example, 
leptin increases spike frequency in a penicillin model of epi-
leptiform activity (19). In addition, leptin enhances N-methyl-
d-aspartate receptor (NMDAR) activity by activating PI3K and 
MAPK (15, 20, 21). Leptin-induced activation of PI3K may 
enhance AMPA receptor (AMPAR) synaptic transmission because 
PI3K increases the surface expression of AMPARs (22, 23). Leptin 
also converts short-term potentiation (STP) into long-term 
potentiation (LTP) (21). Despite these effects, leptin produces a 
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small decrease in basal AMPAR-mediated synaptic currents (21). 
Whether PI3K activation underlies this effect is unknown.
In the experiments described below, we characterize the effects 
of leptin on neuronal excitability. First, we determined whether 
leptin is an anticonvulsant in an in vivo rat model of focal neo-
cortical seizures induced by 4-aminopyridine (4AP) (24). Second, 
we determined whether i.n. leptin administration inhibits gen-
eralized convulsions induced by pentylenetetrazole (PTZ) and 
increases brain leptin levels. Finally, we investigated whether leptin 
inhibits AMPAR-mediated synaptic transmission in hippocampal 
slices via a leptin receptor–mediated mechanism involving JAK 
and PI3K signaling.
Results
Leptin shortens and reduces 4AP-induced neocortical seizure in rats. 
Direct cortical injection of 12.5 nmol 4AP alone in rats consis-
tently induced recurrent seizures typically lasting about 1 minute, 
within 30 minutes of injection (24) (Figure 1). 4AP, a nonspecific 
inhibitor of voltage-gated K+ channels, induced seizures that were 
easy to identify electrographically by their discrete onset, stereo-
typically evolving amplitude and frequency features, and abrupt 
cessation (Figure 1A). Electrographic seizures in rats coinjected 
with 12.5 nmol 4AP + 39 pmol leptin were of lower amplitude 
and noticeably briefer and less frequent than in rats injected with 
12.5 nmol 4AP plus vehicle (Figure 1, B and D). Leptin decreased 
the cumulative seizure duration, 
defined as the total duration of ictal 
activity between 30 and 90 minutes 
after 4AP injection, from 19 ± 9.3 min-
utes (n = 5) to 2.6 ± 1.7 minutes (n = 5; 
P < 0.001, unpaired t test). Leptin did 
not eliminate interictal spikes.
Intranasal leptin administration and 
PTZ-induced seizures. PTZ, a GABAA 
receptor antagonist, is a chemical con-
vulsant that reliably produces general-
ized convulsive seizures (clonic-tonic) 
when administered i.p. The rodent 
PTZ seizure model is a standard animal 
seizure model according to the NIH/
National Institute of Neurological Dis-
orders and Stroke Anticonvulsant Drug 
Development Program (25), possessing 
a quantifiable seizure onset latency, 
easily recognized behavioral seizures, 
and predictive value for anticonvulsant 
efficacy against generalized seizures in 
humans. To determine if leptin inhibits 
seizures in this model, we gave leptin 
i.n. to CD-1 mice 30 minutes before 
giving 75 mg/kg PTZ i.p. Rapid pro-
gression from myoclonus to maximum 
severity generalized clonic-tonic sei-
zures (and often death) in every mouse 
within 10 minutes obviated the need 
to grade seizure severity in this model. 
A leptin dose of 800 μg/kg more than 
doubled the seizure latency compared 
with control (Figure 2A). Leptin doses 
of 8 and 80 μg/kg also increased seizure 
latency, but the differences were not statistically significant (data 
not shown). Leptin was not a proconvulsant at the 3 doses used.
Brain and serum leptin levels after i.n. leptin administration. As 
described previously (8, 9), we observed that serum and brain 
leptin levels increased 30 minutes after i.n. leptin administration. 
Significant increases in serum and brain leptin levels occurred 30 
minutes after administration of 800 μg/kg leptin i.n. (Figure 2, B 
and C). All brains of mice that received 800 μg/kg leptin showed 
leptin levels above 20 pg/mg protein, which we determined to be 
the lowest level of detection with this assay. Leptin doses of 8 and 
80 μg/kg produced smaller increases in serum and brain leptin lev-
els; at both doses, brain leptin was near the detection threshold of 
20 pg/mg protein. All vehicle-treated mice had brain leptin levels 
below 20 pg/mg protein.
Leptin inhibits synaptic responses in mouse hippocampal slices. In 
hippocampal slices, leptin enhances NMDAR-mediated respons-
es and converts STP to LTP (21). This effect was unlikely to have 
accounted for our observation that leptin reduces 4AP-induced 
seizures. However, Shanley et al. (21) also observed modest, 
reversible inhibition of AMPAR-mediated excitatory postsyn-
aptic currents (EPSCs) without changes in the cell input resis-
tance, which raises the possibility that AMPAR inhibition could 
partially explain leptin’s anticonvulsant action. The absence of 
reduced input resistance would argue against increased tonic 
activity of ion channels such as BK or ATP-sensitive K+ (KATP) 
Figure 1
Leptin inhibits in vivo focal neocortical seizures in rats induced by 4AP injections into the left motor 
cortex. (A) Top trace: 15-minute EEG segment recorded from the frontal area ipsilateral to the 
injection site 45 minutes after the injection of 12.5 nmol 4AP. Asterisks indicate 4 individual sei-
zures. Bottom trace: a 1-minute seizure at an expanded time base to illustrate the electrographic 
details of the seizure (underlined). (B) Top trace: 15-minute EEG segment recorded 45 minutes 
after the injection of 12.5 nmol 4AP plus 39 pmol leptin shows 2 shorter, lower-amplitude seizures 
(asterisks). Bottom trace: a 10-second seizure shown at an expanded time base (underlined). Note 
the different time calibration compared with A. (C) Location of the burr hole, injection site, and EEG 
electrodes relative to standard landmarks. (D) Leptin reduced the frequency and duration of 4AP-
induced seizures. Seizure frequency (left) and duration (right) in rats injected with 12.5 nmol 4AP 
alone (white bars; n = 5) or 12.5 nmol plus 39 pmol leptin (black bars; n = 5). Seizure frequency and 
duration for each rat were determined from the 60 minutes of EEG recordings collected between 
30 and 90 minutes after 4AP injection. *P < 0.02 for frequency vs. 4AP alone and *P < 0.001 for 
duration vs. 4AP alone (unpaired t test).
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channels. Therefore, we examined the effect of leptin on CA1 
stratum radiatum field excitatory postsynaptic potentials 
(fEPSPs) evoked by Schaffer collateral stimulation in 
hippocampal slices. Fifteen minutes after bath-applied 0.6 nM 
leptin, a reversible reduction of 81% ± 6% (n = 7 slices, 6 mice) 
occurred in the slope of the fEPSP (Figure 3, A and B). Leptin 
produced a U-shaped, concentration-dependent inhibition of 
the fEPSP slope; 50 nM leptin produced only a 4% ± 7% reduc-
tion in the slope (n = 6 slices, 2 mice) (Figure 3C).
Leptin selectively inhibits the AMPAR component of the fEPSP and 
increases paired pulse facilitation. To evaluate whether leptin differ-
entially inhibited AMPARs and NMDARs, we pharmacologically 
isolated these components of the fEPSP and examined leptin’s 
effects. The CA1 fEPSP slope in nominally Mg2+-free (no added) 
artificial cerebrospinal fluid (ACSF) was 97.0% ± 4% (n = 4 slices, 1 
mouse) of the baseline response obtained in standard ACSF. In the 
same slices, the fEPSP slope was reduced to 26% ± 6% of the base-
line response after the addition of 10 μM 6-cyano-7-nitroquinoxa-
line-2,3-dione (CNQX) to the ACSF to block the AMPAR-mediated 
component of the fEPSP; the fEPSP slope was further reduced to 
5% ± 2% of the baseline response after application of ACSF with 
both 10 μM CNQX and 50 μM d-2-amino-5-phosphonovaleric 
acid (D-APV, an NMDAR antagonist). In ACSF with 50 μM D-APV, 
0.6 nM leptin inhibited the isolated AMPAR component of the 
fEPSP; the fEPSP slope after 30 minutes of leptin application 
was 26% ± 2% of baseline (n = 4 slices, 2 mice; Figure 4A). In Mg2+-
free ACSF with 10 μM CNQX, leptin did not affect the isolated 
NMDAR component of the fEPSP (Figure 4B).
The selective inhibition of the AMPAR component of the fEPSP 
generally supports a postsynaptic mechanism. To further distin-
guish between a pre- and postsynaptic site of action, we examined 
the effect of leptin on paired pulse facilitation. We compared the 
paired pulse ratio (P2/P1, where P1 is the slope of the first fEPSP 
and P2 is the slope of the second fEPSP) at baseline and after apply-
ing 0.6 nM leptin for 20 minutes. Leptin reduced the slope of both 
fEPSPs in a pair (Figure 4C, arrows) and slightly but significantly 
increased the paired pulse ratio (Figure 4D), which suggested an 
additional presynaptic inhibitory mechanism.
Figure 2
Intranasal leptin inhibits in vivo PTZ-induced generalized convulsive 
seizures and elevates serum and brain leptin levels in mice. (A) In 6- to 
8-week-old CD-1 mice, 800 μg/kg leptin (n = 15) given i.n. 30 minutes 
before the i.p. injection of 75 mg/kg PTZ significantly increased the 
latency to behaviorally assessed generalized clonic-tonic seizures. 
*P < 0.002 compared with mice that received vehicle (n = 16). (B) Cor-
tex leptin per milligram of cortex protein (*P < 0.001). (C) Serum leptin 
concentrations increased significantly (*P < 0.0001) after 800 μg/kg 
leptin i.n. compared with vehicle. The Mann-Whitney U test was used 
for the statistical analysis.
Figure 3
Leptin inhibits CA1 fEPSPs in mouse hippocampal slices. (A) Rep-
resentative tracings of Schaffer collateral evoked fEPSPs recorded 
in CA1 at baseline during perfusion of ACSF (Baseline), after a 20-
minute perfusion with 0.6 nM leptin (Leptin), and after a 30-minute 
washout with ACSF (Recovery). Calibration: 2 ms, 0.1 mV. (B) Time 
course of the fEPSP slope demonstrates the inhibition of fEPSP during 
a 20-minute application of 0.6 nM leptin (indicated by the bar), which 
almost completely recovers after a 30-minute washout with ACSF 
(n = 7 slices, 6 mice). fEPSP slopes at each time point were normal-
ized to the slope of the baseline fEPSPs, which is indicated by the 
dotted line. Only every third point is shown for clarity. (C) U-shaped 
concentration-response curve of leptin inhibition of the fEPSP slope 
demonstrates maximal inhibition at 0.6 nM and minimal inhibition at 
0.006 and 50 nM leptin (n = 6 slices, 2 mice).
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Given that the above results do not definitively support a pre-
synaptic mechanism, we used whole-cell voltage clamp record-
ings from CA1 pyramidal neurons to examine the effect of 
leptin on AMPAR- and NMDAR-mediated EPSCs. Leptin inhib-
ited AMPAR-mediated EPSCs and fEPSPs in a similar manner, 
except that only partial recovery occurred with washout (Figure 
5A). Leptin at 0.6 nM reduced the amplitude of AMPAR EPSCs 
recorded at –70 mV by 56% ± 20% (n = 9); a lower and a higher 
concentration of leptin produced no change (Figure 5B). In 2 
other cells, 0.6 nM leptin did not inhibit the AMPAR-mediated 
EPSC; these cells were not included in the amplitude analysis. 
Leptin produced a larger increase in paired-pulse facilitation of 
AMPAR-mediated EPSCs than in fEPSPs (Figure 5C). In 8 of 11 
cells, leptin also significantly lengthened the EPSC latency from 
3.2 ± 0.5 to 4.3 ± 1.0 ms (P < 0.02, paired t test), with partial recovery 
to baseline on leptin washout. Leptin clearly inhibited the EPSC 
in 2 of the 3 cells that exhibited no change in EPSC latency. The 
mean amplitude of NMDAR-mediated EPSCs recorded at +20 mV 
in ACSF containing 2 mM CaCl2, 1 mM MgCl2, and 10 μM 
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-
dione (NBQX) — a selective AMPAR antagonist — was 
97% ± 3.2% of the control (n = 5 cells). Together these 
results suggest that leptin inhibits AMPAR-mediated 
synaptic transmission pre- and postsynaptically.
Leptin inhibits low magnesium–induced spiking in cultured 
hippocampal neurons. To determine whether leptin reduces 
neuronal hyperexcitability at concentrations comparable 
with those that inhibit AMPAergic EPSPs and EPSCs in slic-
es, we examined the effect of leptin on the bursts of action 
potentials induced in cultured hippocampal neurons by 
nominally Mg2+-free extracellular solution (26, 27). Cul-
tured hippocampal neurons generally fire isolated action 
potentials when Mg2+ is present in the extracellular solu-
tion. When the extracellular solution contains no added 
Mg2+, the neurons fire bursts of action potentials superim-
posed on a depolarizing wave that resembles a paroxysmal 
depolarizing shift (Figure 6A). Leptin decreased action 
potential bursting (Figure 6B, 1 nM leptin), which partial-
ly reverted to baseline spike frequency after leptin wash-
out (Figure 6C). Cumulative data show that 1 and 10 nM 
leptin, but not 0.1 nM leptin, significantly decreased 
action potential bursting on the basis of a comparison of 
spike frequency in the same neuron before and after leptin 
application (Figure 6D). Thus, leptin decreases neuronal 
hyperexcitability in cultured hippocampal neurons in the 
same concentration range that decreases AMPAR-medi-
ated EPSCs in hippocampal slices.
In separate experiments we examined whether leptin 
alters neuronal input resistance or action potential prop-
erties. We used cultured hippocampal neurons because 
they are more compact electrically, which makes leptin-
induced changes in input resistance easier to detect. 
Leptin concentrations of 0.1, 1, and 10 nM had no effect 
on neuronal input resistance or action potential proper-
ties (threshold, amplitude, or duration; see Supplemental 
Table 1; supplemental material available online with this 
article; doi:10.1172/JCI33009DS1).
JAK and PI3K inhibitors prevent leptin inhibition of fEPSP. 
Leptin receptors are class I cytokine receptors that sig-
nal via association with JAKs. When leptin binds to the 
long form of the leptin receptor, Ob-Rb, JAK2 is activated and 
both proteins are subsequently phosphorylated, which results in 
the recruitment and activation of downstream signaling path-
ways in hematopoietic, adipocyte, pancreatic, and muscle cells 
(28, 29). Evidence indicates that JAK/PI3K signaling is impor-
tant in neurons (30–32), and leptin-mediated effects in neurons 
have been shown to be inhibited by JAK inhibitors (33–35) and 
PI3K inhibitors (11, 36).
Therefore, we examined whether JAK and PI3K inhibitors 
prevent leptin from decreasing CA1 fEPSPs. After baseline 
EPSP recordings were obtained, application of the JAK2 inhibi-
tor AG490 alone (20 μM; 45–60 minutes) had no effect on the 
fEPSP slope (data not shown). However, preincubating slices 
with AG490 for at least 3 hours prevented 0.6 nM leptin from 
inhibiting CA1 fEPSPs (Figure 7A). We also used 2 structurally 
unrelated PI3K inhibitors, LY294002 and wortmannin, to inves-
tigate whether PI3K activation is necessary for leptin’s effect. 
Application of LY294002 (16 μM) or wortmannin (50 nM) 
alone had no effect on baseline fEPSP slope (data not shown). 
Preincubation with either agent for at least 3 hours completely 
Figure 4
Leptin selectively inhibits the AMPAR-mediated component of the CA1 field 
excitatory postsynaptic potentials (fEPSPs) in mouse hippocampal slices. (A) 
Leptin inhibited the AMPAR component of the CA1 fEPSP. Time course of the 
fEPSP slope for the AMPAR component after bath-applied 0.6 nM leptin as 
indicated by the bar (n = 4 slices, 2 mice). The AMPAR component was isolated 
by adding the N-methyl-d-aspartate (NMDA) antagonist D-APV (50 μM) as indi-
cated by the bar. (B) In contrast, leptin did not inhibit the NMDAR component 
of the CA1 fEPSP. Time course of the fEPSP slope for the NMDA component 
after bath-applied 0.6 nM leptin as indicated by the bar (n = 6 slices, 4 mice). 
The NMDAR component was isolated by adding the AMPAR antagonist CNQX 
(10 μM) in Mg2+-free ACSF. Data in A and B were analyzed as in Figure 3B. The 
bars indicate when Mg2+-free ACSF and leptin were applied. (C and D) Leptin 
enhances paired-pulse facilitation. (C) Superimposed representative pairs of 
CA1 fEPSPs from the same slice demonstrate fEPSP inhibition and increased 
paired pulse facilitation in 0.6 nM leptin (arrows). Interstimulus interval: 25 ms; 
calibration: 4 ms, 0.2 mV. (D) Cumulative data from 5 slices (5 mice) comparing 
the paired pulse facilitation ratio (PPF = P2/P1, where P1 is the slope of the first 
fEPSP and P2 is the slope of the second fEPSP) before and after the applica-
tion of 0.6 nM leptin for 20 minutes (*P < 0.02, paired t test).
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prevented leptin-induced inhibition of fEPSPs (Figure 7, B and 
C). These data indicate that leptin-induced inhibition of CA1 
hippocampal AMPAR synaptic responses requires activation of 
the JAK2/PI3K signaling pathway.
Effects of leptin in db/db mice. Leptin acts systemically to orches-
trate complex biological effects through its specific cellular recep-
tor. As mentioned above, the long form of Ob-Rb is capable of 
full signal transduction. To address whether leptin inhibition 
of AMPAR-mediated synaptic responses requires leptin receptor 
activation, we compared the effects of leptin on CA1 fEPSPs in 
hippocampal slices from db/db mice, which are Ob-Rb deficient 
(37), and from wild-type C57BLKS/J mice, the background strain 
of db/db mice. In slices from C57BLKS/J mice, leptin inhibited 
synaptic responses as observed in CD-1 mice; CA1 fEPSP slopes 
were 34% ± 3 % (n = 6 slices, 3 mice) of baseline after perfusion 
with 0.6 nM leptin for 30 minutes (Figure 8). However, in slices 
from db/db mice, leptin did not alter CA1 fEPSP slopes; the slopes 
were 93% ± 12% (n = 10 slices, 3 mice) of baseline after application 
of 0.6 nM leptin for 30 minutes. This result indicates that Ob-Rb 
activation is necessary for leptin to inhibit AMPAR-mediated CA1 
hippocampal synaptic responses.
Discussion
Leptin is an anticonvulsant in a focal and a generalized seizure model. 
The ketogenic diet, an effective anticonvulsant therapy, elevates 
serum leptin levels in rodents (16, 17). Leptin reduces neuronal 
excitability and epileptiform activity in vitro (11), and Durakogl-
ugil et al. (15) postulated, based on leptin’s actions in vitro, that 
leptin is an endogenous anticonvulsant. Accordingly, we found 
that leptin decreased the frequency and duration of 4AP-induced 
focal neocortical seizures in rats. In addition, i.n. administered 
leptin (800 μg/kg) elevated brain leptin and increased the latency 
of PTZ-induced generalized seizures. Two lower doses of leptin (8 
and 80 μg/kg) produced a trend toward increased PTZ-induced 
seizure latency without a consistent elevation in brain leptin with 
our assay. We speculate that the lower leptin doses produce higher 
Figure 5
Leptin inhibits AMPAR-mediated EPSCs obtained from voltage-
clamped CA1 pyramidal neurons in mouse hippocampal slices. (A) 
Representative tracings of Schaffer collateral evoked whole-cell 
EPSCs recorded from a voltage-clamped CA1 neuron at –70 mV at 
baseline during perfusion of ACSF containing 2 mM CaCl2 and 1 mM 
MgCl2 (Baseline), after a 10-minute perfusion with 0.6 nM leptin 
(Leptin), and after a 20-minute washout with ACSF (Recovery). Calibra-
tion: 5 ms, 25 pA. (B) Leptin inhibited AMPAR-mediated EPSCs with a 
U-shaped dose-response relation. Peak amplitudes of AMPAR-medi-
ated EPSCs after a 10-minute perfusion with various leptin concentra-
tions expressed as a percentage of the peak amplitude of the baseline 
EPSC (n = 5–9 cells). *P < 0.001 for 0.6 vs. 0.06 nM and *P < 0.01 
for 0.6 vs. 50 nM leptin (ANOVA followed by Tukey-Kramer’s test for 
multiple comparisons). (C) Leptin-enhanced paired pulse facilitation. 
The paired-pulse ratio was calculated as in Figure 4 by using peak 
amplitudes of pairs of EPSCs evoked with an interstimulus interval of 
25 milliseconds in 0.6 nM leptin. n = 8 cells, *P < 0.02 (paired t test).
Figure 6
Leptin inhibits low magnesium–induced spiking in cultured mouse 
hippocampal neurons. (A) Whole-cell patch recordings from cultured 
hippocampal neurons in current clamp configuration spontaneously 
fire action potentials in nominally magnesium-free external solution. 
Baseline membrane potential: –57 mV. Calibration for A1–A3: 10 s, 
30 mV. (B) Leptin (1 nM) reduces action potential firing frequency 
by 30%–40%. (C) Action potential firing recovers close to baseline 
frequency after leptin washout. (D) Cumulative data comparing spike 
frequency in low magnesium before (filled squares) and after (open 
squares) application of different leptin concentrations. Each filled 
and open symbol connected by a line represents 1 cell and its firing 
frequency before and after leptin. Therefore, each line represents 1 
matched data pair; some data points are superimposed on each other. 
The mean ± SD values are presented beside each data set with a 
larger symbol. A significant reduction in spike frequency was produced 
by 1.0 nM (n = 13 cells) and 10 nM (n = 11 cells), but not by 0.1 nM 
(n = 12 cells) leptin (paired t test).
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than basal brain leptin levels, which are below the detection level 
of the assay, yet impart some anticonvulsant effect not robust 
enough to produce a statistically significant group effect. We 
conclude that leptin is an anticonvulsant against acute seizures 
induced by 2 convulsants with different mechanisms of action 
and against both focal and generalized seizures in vivo. Whether 
leptin is effective against sporadic seizures in chronic epilepsy is 
unclear and requires further study. It is possible that leptin coun-
ters acute emergent seizures but is not an effective anticonvul-
sant when administered chronically. Importantly, we found no 
evidence that leptin has proconvulsant effects, despite observa-
tions that raise the possibility that leptin might increase neuronal 
excitability and worsen seizures (19, 21).
Leptin inhibits AMPAergic synaptic responses and low magnesium–
induced spiking. We found that a narrow range of leptin concentra-
tions inhibit AMPAR-mediated synaptic responses. A maximally 
effective leptin concentration of 0.6 nM inhibited AMPAR-medi-
ated CA1 fEPSP by 80% and CA1 EPSCs by 60%; lower and higher 
concentrations produced less inhibition. Results similar to ours 
were reported by Shanley et al. (21), who found that 50 nM leptin 
inhibits AMPAR-mediated CA1 EPSCs by 20%; however, they 
did not report the effects of lower leptin concentrations. Other 
effects of leptin, such as those on the modulation of CA1 LTP 
in hippocampal slices (38, 39), the medial perforant path LTP in 
vivo (40), and intracellular Ca2+ (11, 39), also showed a U-shaped 
dependence on leptin concentration. These results suggest that 
the effects of leptin are highly regulated and complex.
Our results did not allow us to determine which of leptin’s many 
potentially anticonvulsant effects contribute to its anticonvulsant 
effect in vivo. In addition to the inhibition of AMPAR-mediated 
synaptic transmission, leptin’s anticonvulsant effect may result 
from NMDAR inhibition (39) or BK channel activation (11, 13, 36). 
Our results are consistent with those of a model in which the inhi-
bition of AMPAR-mediated synaptic transmission contributes to 
leptin’s anticonvulsant effect at low (nanomolar) concentrations, 
and other mechanisms contribute at higher concentrations. We 
found that low (nanomolar) leptin concentrations inhibit experi-
mentally induced bursting in cultured neurons (Figure 6). This 
result is consistent with the inhibition of AMPAR-mediated syn-
aptic transmission contributing to leptin’s anticonvulsant effect. 
However, we expect leptin to have a narrow therapeutic range as 
an anticonvulsant in vivo if the inhibition of AMPAR-mediated 
synaptic transmission were its only anticonvulsant mechanism 
based on the U-shape concentration response curve. However, 
leptin does not appear to have a narrow therapeutic range as an 
anticonvulsant in vivo. Thus, we predict that other mechanisms, 
such as the induction of LTD (15), the activation of BK (11, 13, 
36), and the activation of KATP channels (41), may contribute to 
leptin’s anticonvulsant effects at higher leptin doses. These effects 
of leptin require 100-fold higher leptin concentrations than need-
ed to inhibit AMPAR-mediated synaptic transmission.
Differential effects of leptin on AMPAR and NMDAR responses. 
Leptin can modulate AMPAR-mediated synaptic responses by 
altering NMDAR-dependent forms of long-term synaptic plas-
ticity. In the hippocampus, leptin enhances LTP (38–40), con-
verts STP into LTP (21), and induces a novel form of LTD (15). 
Figure 7
Leptin inhibition of CA1 fEPSPs in mouse hippocampal slices depends 
on JAK2 and PI3K activation. The JAK2 inhibitor AG490 and the PI3K 
inhibitors LY294002 and wortmannin prevented leptin-induced fEPSP 
inhibition. Time course of CA1 fEPSP slopes after the application of 
0.6 nM leptin as indicated by the bar in slices pretreated for at least 
3 hours in 20 μM AG490 (n = 5 slices, 3 mice) (A), 16 μM LY294002 
(n = 7 slices, 2 mice) (B), or 50 nM wortmannin (n = 6 slices, 2 mice) 
(C). Data were analyzed as in Figure 3B.
Figure 8
Leptin inhibition of CA1 field excitatory postsynaptic potentials 
(fEPSPs) in mouse hippocampal slices depends on the long form of 
the leptin receptor. Leptin did not inhibit fEPSPs in hippocampal slices 
obtained from leptin receptor (Ob-Rb)–deficient db/db mice, but did 
inhibit fEPSPs in slices from wild-type C57BLKS/J mice. The time 
course of CA1 fEPSPs after the application of 0.6 nM leptin is indicated 
by the bar for slices from db/db mice (n = 6 slices, 3 mice) (triangles) 
and C57BLKS/J mice (n = 10 slices, 3 mice) (squares). Data were 
analyzed as in Figure 3B.
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The leptin-induced inhibition of AMPAergic synaptic responses 
reported herein is not a form of NMDAR-dependent long-term 
synaptic plasticity because the inhibition reverses on leptin 
removal. The inhibition we observed occurred independently 
of NMDAR activation because it occurred when Mg2+ or D-APV 
blocked NMDARs. Moreover, to inhibit AMPAergic synaptic 
responses, we used nearly 100-fold lower leptin concentrations 
than required to enhance NMDAR responses or modulate long-
term synaptic plasticity (15, 21).
The increase in paired-pulse facilitation of CA1 fEPSPs and 
EPSCs suggests that leptin inhibits AMPAR-mediated synap-
tic transmission presynaptically. Consistent with a presynaptic 
effect, 0.1 nM leptin, a concentration that inhibits CA1 fEPSPs, 
did not alter spontaneous miniature EPSC amplitudes in CA1 
neurons (39). A potential presynaptic mechanism based on a 
well-established leptin effect is BK channel activation (11, 13, 36). 
Although BK channel activation contributes to action potential 
repolarization in CA3 pyramidal neurons, BK channel activation 
may only alter transmitter release at CA3-CA1 synapses under 
hyperexcitable conditions (42, 43). In addition, leptin activation 
of BK channels requires much higher leptin concentrations than 
needed to inhibit AMPAR-mediated synaptic transmission. Thus, 
BK channel activation may contribute to the anticonvulsant 
effect of leptin in vivo, but it may not be the primary mechanism 
by which leptin inhibits AMPAR-mediated synaptic transmission 
under normal conditions.
We also observed that leptin selectively inhibited the AMPAR 
component of the CA1 fEPSP and EPSC. A differential effect on 
the AMPA or NMDA component of an EPSP or EPSC is evidence 
of a postsynaptic effect (44, 45). Despite the marked differences in 
NMDAR and AMPAR sensitivity to glutamate, presynaptic manip-
ulations do not selectively affect one component (45). A postsyn-
aptic effect is consistent with the tendency for 0.1 nM leptin to 
decrease depolarizations induced by iontophoretic applications 
of quisqualate, an AMPAR agonist, in CA1 neurons (39). Thus, 
our results suggest that leptin inhibits AMPAR-mediated synaptic 
transmission pre- and postsynaptically.
Leptin receptor activation of the JAK2/PI3K pathway inhibits AMPAR-
mediated fEPSPs. Our results with 1 JAK2 inhibitor and 2 PI3K 
inhibitors and db/db mice suggest that leptin inhibits AMPAergic 
synaptic responses by binding to its receptor and activating the 
JAK2/PI3K pathway. We examined this pathway because leptin 
enhances NMDAR-mediated responses (21) and activates BK and 
KATP channels (13) via this pathway. We also examined this pathway 
because AMPARs complex with PI3K (22). Consequently, our results 
raise the possibility of a postsynaptic JAK2/PI3K-dependent mecha-
nism for the inhibition of AMPAR-mediated synaptic transmission 
by leptin. However, PI3K activation causes AMPAR insertion (22, 
23), which should result in enhanced synaptic transmission. Such a 
mechanism would account for some leptin concentrations enhanc-
ing long-term synaptic plasticity at excitatory synapses (21, 38–40). 
PI3K also regulates endocytosis (46, 47) and thereby may modulate 
AMPAR internalization (48). We speculate that different concen-
trations of leptin can produce opposing effects on AMPAR-medi-
ated synaptic responses via a common PI3K signaling pathway (22) 
by differently modulating the sources and subcellular locations of 
leptin-dependent intracellular calcium changes.
Conclusion. Our data support the hypothesis that leptin is an 
anticonvulsant in vivo because the leptin receptor activates the 
JAK2/PI3K pathway and inhibits AMPAR-mediated synaptic 
transmission by a pre- and postsynaptic mechanism. Leptin’s 
potential as a clinically useful anticonvulsant is enhanced because 
i.n. administration increases brain leptin levels, and leptin inhibits 
focal and generalized seizures (8). Although other anticonvulsants 
inhibit glutamatergic transmission, leptin may afford a broader 
range of treatment strategies because it is a peptide. For example, 
gene delivery strategies (49) might enable inducible leptin expres-
sion in an epileptogenic cortical region refractory to conventional 
anticonvulsants and not amenable to surgical treatment. Dietary 
modifications can increase systemic leptin levels (16, 17), and its 
transport into the brain may be enhanced by manipulating its 
endogenous transporters (7). Our results highlight leptin’s poten-
tial for treating epilepsy by targeting brain leptin receptors and 
underscore the importance of understanding its regulation and 
physiological actions in the CNS.
Methods
Animals. Male Sprague-Dawley rats, Swiss-Webster mice, and CD-1 mice 
were purchased from Charles River Laboratories. Male db/db (Stock 
000642) and C57BLKS/J (Stock 000662) mice were purchased from Jack-
son Laboratory. Animal care and experimentation methods conformed to 
the Public Health Service Guide for the Care and Use of Laboratory Ani-
mals and the American Veterinary Medical Association Panel on Euthana-
sia Guidelines and were approved by the Washington University School of 
Medicine Animal Studies Committee.
Tissue preparation for electrophysiology. Primary dissociated hippocampal 
cultures were prepared from E15 Swiss-Webster mouse embryos on glass 
coverslips with preapplied glial feeder layers as described previously (50). 
Cells were used for patch-clamp recordings between 9 and 14 days in vitro. 
Hippocampal slices were prepared as described previously (51) from 6- to 
8-week-old mice for extracellular recordings and from 3-week-old mice for 
whole-cell recording. Mice were killed under halothane at approximately 
the same time each morning because of leptin’s diurnal variation. Brains 
were rapidly removed; placed in ice-cold ACSF consisting of 124 mM NaCl, 
5 mM KCl, 2.5 mM CaCl2, 1.3 mM MgCl2, 1.3 mM NaH2PO4, 22 mM 
NaHCO3, and 10 mM glucose; and saturated with 95% O2/5% CO2 to a 
pH of 7.4. Transverse hippocampal slices (400 μm) were prepared with a 
vibratome and incubated for at least 1 hour in ACSF at room temperature 
before the recording experiments were conducted.
Materials. Recombinant mouse leptin, d-APV, and the disodium salt of 
CNQX were purchased from Sigma-Aldrich. AG490, LY294002, and wort-
mannin were obtained from Calbiochem. Leptin stock solution consisted 
of 1 mg lyophilized leptin solubilized in 0.5 ml 15 mM HCl followed by 
the addition of 0.3 ml 7.5 mM NaOH to raise the pH to about 5.2. The 
resulting stock solution was diluted in ACSF for cortical injection or in vitro 
electrophysiology experiments. To enhance CNS absorption after i.n. leptin 
administration (9), 1 mg lysophosphatidylcholine (LPC; Sigma-Aldrich) 
was dissolved in 0.2 ml 0.9% saline and mixed with 0.8 ml of the leptin stock 
solution to a final concentration of 1 mg/ml leptin and 0.1% LPC.
Leptin assay. Serum and brain leptin levels were measured with the use 
of a commercial mouse ELISA kit (EZML-82K; Linco Research/Millipore 
Corp.). Leptin standards containing concentrations below 0.1 ng/ml 
were indistinguishable from the blanks, which indicated that the lower 
limit of detection is 0.1 ng/ml leptin. Therefore, all samples with read-
ings below the average 3 SDs for a blank were considered to have an 
undetectable leptin level, i.e., less than 0.1 ng/ml leptin. Brain or serum 
samples with higher than the maximum quantifiable level of leptin were 
diluted with assay buffer to obtain measurements within the range of 
the leptin standards in the kit, and values were calculated using the 
appropriate dilution factor.
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Mice were deeply anesthetized, and then a thoracotomy was performed 
to expose the heart. Blood was obtained by right atrium puncture and cen-
trifuged at 15,900 g for 15 minutes at 4°C. Next, intracardiac perfusion was 
performed via the left ventricle using cold (0–4°C) PBS for 5–7 minutes, 
which was followed by brain removal. Pieces of frontal-parietal cerebral 
cortex and serum samples were immediately frozen on dry ice and stored at 
–80°C until processed. Brain leptin levels were measured in some animals 
that received PTZ. These animals were not perfused, but control experi-
ments showed that the leptin from the blood remaining in the nonper-
fused brain did not produce detectable brain leptin levels.
The leptin ELISA was performed on brain and serum samples accord-
ing to the manufacturer’s instructions. Brain levels were measured in 
samples (~30–50 mg) prepared by mixing with 10 ml lysis buffer per 1 mg 
tissue. Lysis buffer consisted of 160 mM KCl, 25 mM HEPES, and 1% 
Triton X-100. Samples were sonicated and mixed on a micro-rotator for 
1 hour and then centrifuged for 20 minutes at 4°C at 15,900 g. The 
supernatant was stored at –80°C until analyzed. For leptin measure-
ments, different dilutions of supernatant were made with assay buffer 
from the kit. Leptin levels in these samples of brain tissue were nor-
malized to protein levels, which were determined using a commercially 
available kit (Micro BCA Protein Assay Kit; Pierce Biotechnology Inc.). 
All measurements were done in triplicate.
Neocortical seizure model. Four- to six-week-old male Sprague-Dawley rats 
were anesthetized with halothane (4%) and then placed on a stereotaxic 
frame (David Kopf Instruments). A burr hole was drilled over the left hemi-
sphere at a site 2 mm anterior to the bregma and 2.5 mm lateral to midline 
with a dental drill. After surgery, halothane was reduced to 1%–2% and 1 ml 
ACSF containing 12.5 mM 4AP (12.5 nmol) was injected from a glass 
micropipette (tip diameter: 100 μm) into the motor cortex 0.5 mm deep to 
the cortical surface with a commercial injector (Nanoject; Drummond Sci-
entific). This model produces frequent repetitive seizures narrowly local-
ized to the site of injection (24). Leptin-treated rats were injected with 1 ml 
ACSF containing 12.5 mM 4AP and 39 μM leptin (39 pmol). Two screw 
electrodes were placed symmetrically over each hemisphere and differen-
tially recorded the EEG in a referential montage with the use of standard 
AC EEG amplifiers (Grass-Telefactor). The EEG was digitized (200 Hz) and 
stored with the use of PC-based commercial hardware (Digidata and Axo-
scope; Axon Instruments). EEG recordings started 15 minutes before and 
ended 90 minutes after the 4AP injection. The EEG was visually analyzed 
by a reviewer blinded to the experimental protocol to determine the num-
ber of seizures in a record and seizure duration. A seizure was defined as 
a discrete electrographic event with an onset consisting of low-amplitude, 
high-frequency discharge followed by an evolving rhythmic, repetitive, 
high-amplitude discharge with a distinct termination.
PTZ generalized seizure model. Six- to eight-week-old male CD-1 mice were 
divided into a vehicle-treated control group and a leptin-treated group. A 
20-mg/ml PTZ stock was made by using sterile 0.9% saline, and each mouse 
received 75 mg/kg PTZ via i.p. injection. Leptin-treated rats received 8, 80, 
or 800 μg/kg in 0.1% LPC i.n. 30 minutes before PTZ administration. Con-
trol mice received LPC vehicle without i.n. leptin. All mice, regardless of 
the leptin dose administered, received a total volume of 20 μl. An observer, 
blinded to the treatment administered, measured the latency to the onset 
of the first generalized convulsive seizure as assessed behaviorally.
Electrophysiology experiments. Hippocampal slices were transferred to a 
submerged recording chamber (Warner Instruments) and perfused con-
tinuously at a rate of 3 ml/min with ACSF (see above) at 30°C. Glass 
electrodes filled with 2 M NaCl (resistance: 3–5 MΩ) were used to record 
fEPSPs from CA1 stratum radiatum. EPSPs were evoked via stimulation 
of the Schaffer collateral pathway through a bipolar electrode (David 
Kopf Instruments) at a frequency of 0.0167 Hz. In all experiments, a stim-
ulus intensity that evoked an EPSP with 50% of the maximal slope was 
used. The fEPSP slopes obtained during 15–20 minutes of stable base-
line recording were averaged and then used to normalize fEPSP slopes 
during drug application and washout to combine data from different 
brain slices. EPSCs were recorded in voltage-clamp configuration from 
individual CA1 pyramidal neurons in hippocampal slices prepared as 
above from P21–P28 male CD-1 mice. Neurons were identified by infra-
red differential interference contrast videomicroscopy (52). The ACSF 
was slightly modified for whole-cell recording in slices to contain 2 mM 
CaCl2 and 1 mM MgCl2. NMDAR-mediated EPSCs were isolated by add-
ing 10 μM NBQX. Patch electrodes for slice recording were filled with an 
internal solution containing 140 mM potassium gluconate, 5 mM NaCl, 
1 mM CaCl2, 2 mM MgATP, 10 mM EGTA, and 10 mM HEPES (pH 7.3). 
Whole-cell recording from hippocampal neuron cultures were performed 
by using an internal solution containing mM 140 mM potassium gluco-
nate, 4 mM NaCl, 0.5 mM CaCl2, 2 mM MgATP, 0.5 mM Na2GTP, 5 mM 
EGTA, and 10 mM HEPES (pH 7.2) and an external solution containing 
140 mM NaCl, 5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 
and 10 mM glucose (pH 7.3). Analog data were obtained with an Axo-
patch 200B amplifier, digitized at 10 kHz, and analyzed with an Axon 
Instruments Digidata 1322A and pClamp9 (Molecular Devices).
Statistics. All data are presented as the mean ± SD. Statistical analyses 
were performed by using paired or unpaired 2-tailed t tests with appro-
priate corrections as indicated; ANOVA followed by Tukey-Kramer’s or 
Kruskal-Wallis with Dunn’s post test were used for comparisons between 
multiple groups. Statistical significance was set at P < 0.05.
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